Memorial Sloan Kettering Cancer Center (MSKCC)In September 2014, SELLAS announced an exclusive global collaboration and exclusive license agreement with Memorial Sloan Kettering Cancer Center (MSKCC) for the development, marketing and commercialization of MSKCC’s proprietary WT1 cancer immunotherapy.

WT1 is over-expressed in many human cancers, including most blood cancers and many solid tumors, including mesothelioma, and cancers of the ovary, lung, gastrointestinal tract, breast, and prostate. The National Cancer Institute recently ranked WT1 as the top target for cancer immunotherapy. MSKCC researchers have already shown the potential of this immunotherapy to safely immunize patients against the WT1 antigen in several clinical trials.


LSNE Contract ManufacturingFounded in 1997, LSNE has an impressive history of serving global pharmaceutical, biotechnology and medical device companies. LSNE is differentiated by its high-quality cGMP aseptic fill-finish capabilities, a nd expertise in and ability to scale lyophilization.


PolyPeptide Group The PolyPeptide Group is a contract manufacturing organization for peptides and peptide related molecules. The group is one of the world’s largest independent contract manufacturers of therapeutic peptides for the cosmetic, pharmaceutical and veterinary markets employing more than 450 people in six manufacturing sites located in France, India, Scandinavia and the USA. The company manufactures over one third of all approved peptide drug substances (22 of 62 approved products worldwide) accounting for over 25% of the sales of outsourced peptide therapeutics worldwide.

merck logo msd logo

Merck & Co., Inc. Basket Study
SELLAS entered into a Clinical Trial Collaboration and Supply Agreement for the conduct of a combination clinical trial Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada), whereby galinpepimut-S will be administered in combination with MSD's anti-PD-1 therapy pembrolizumab (Keytruda®) in a Phase 1/2 trial enrolling patients with WT1-positive relapsed or refractory tumors in multiple cancer indications, including both hematologic malignancies and solid tumors. The primary indication currently being studied is ovarian cancer (second or third line).

bms logo

Bristol-Myers Squibb (BMS) GPS plus nivolumab (ovarian cancer)
GPS plus nivolumab (MPM)

An investigator-sponsored trial (IST) was conducted with GPS in combination with nivolumab (Opdivo®; BMS). This Phase 1/2 clinical trial was an open label, single-center, investigator-sponsored, 10 patient study enrolling patients with ovarian cancer who relapsed at least once and returned to complete clinical remission after additional (first or subsequent) salvage chemotherapy.

An IST is being conducted with GPS in combination with nivolumab in patients with malignant pleural mesothelioma (MPM) at MSKCC. Enrollment is ongoing in this Phase 1 open-label clinical study of GPS in combination with nivolumab in patients with MPM who harbor relapsed or refractory disease after having received frontline standard of care multimodality therapy.


3D Medicines, Inc.GPS
GPS Plus
In December 2020, SELLAS entered into an exclusive license agreement with 3D Medicines Inc., a China-based biopharmaceutical company developing next-generation immuno-oncology drugs, for the development and commercialization of GPS, as well as SELLAS’ next generation heptavalent immunotherapeutic GPS+, which is at preclinical stage, across all therapeutic and diagnostic uses in the Greater China territory (mainland China, Hong Kong, Macau and Taiwan). SELLAS has retained sole rights to GPS and GPS+ outside of the Greater China area.

GenFleet Therapeutics logo

GenFleet Therapeutics (Shanghai) Inc.In March of 2022 Sellas entered into an exclusive license agreement with GenFleet Therapeutics (Shanghai) Inc., a clinical-stage biotechnology company focused on therapies in oncology and immunology, to develop, manufacture, and commercialize a small molecule cyclin-dependent kinase 9, or CDK9, inhibitor for use in all countries outside of the Greater China area.

For enquiries related to partnering opportunities, please email: